钠-葡萄糖共转运蛋白2抑制剂改善骨骼肌代谢与功能的研究进展

doi:10.16352/j.issn.1001-6325.2026.02.0278

基础医学与临床 ›› 2026, Vol. 46 ›› Issue (2): 278-281.doi: 10.16352/j.issn.1001-6325.2026.02.0278

钠-葡萄糖共转运蛋白2抑制剂改善骨骼肌代谢与功能的研究进展

施景文, 王雅冰, 孙颖^*

首都医科大学附属北京友谊医院老年医学科,北京 100050

收稿日期:2025-04-30 修回日期:2025-06-23 出版日期:2026-02-05 发布日期:2026-01-21
通讯作者: ^* ysun13@163.com
基金资助:
新一代人工智能国家科技重大专项(2021ZD0111002)

Advances in sodium-glucose cotransporter-2 inhibitors for improving skeletal muscle metabolism and function

SHI Jingwen, WANG Yabing, SUN Ying^*

Department of Geriatrics, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received:2025-04-30 Revised:2025-06-23 Online:2026-02-05 Published:2026-01-21
Contact: ^* ysun13@163.com

摘要/Abstract

摘要： 钠-葡萄糖共转运蛋白2抑制剂(SGLT2is)是2型糖尿病、慢性心力衰竭的指南推荐药物之一。目前越来越关注SGLT2is对身体成分的影响,例如脂肪、骨骼肌,特别是骨骼肌。SGLT2is通过增强骨骼肌葡萄糖代谢、脂肪酸代谢及氨基酸代谢,并且抑制萎缩通路相关分子表达,还可以减轻骨骼肌氧化应激及炎性反应,从而改善骨骼肌功能,旨在为临床医师对于老年慢性疾病合并骨骼肌萎缩患者带来新的诊疗思路。

关键词: 钠-葡萄糖共转运蛋白2抑制剂, 骨骼肌

Abstract: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are guideline-recommended medications for type 2 diabetes mellitus and chronic heart failure. Increasing attention is being paid to the effects of SGLT2is on body composition, including adipose tissue and skeletal muscle, with particular emphasis on the latter. SGLT2is improve skeletal muscle function through multiple mechanisms: enhancing glucose, fatty acid, and amino acid metabolism in skeletal muscle; suppressing the expression of atrophy pathway-related molecules; and alleviating oxidative stress and inflammatory responses in skeletal muscle. Collectively, these findings provide clinicians with novel diagnostic and therapeutic perspectives for managing elderly patients with chronic diseases accompanied by skeletal muscle atrophy.

Key words: sodium-glucose cotransporter 2 inhibitors, skeletal muscle

中图分类号:

R592

施景文, 王雅冰, 孙颖. 钠-葡萄糖共转运蛋白2抑制剂改善骨骼肌代谢与功能的研究进展[J]. 基础医学与临床, 2026, 46(2): 278-281.

SHI Jingwen, WANG Yabing, SUN Ying. Advances in sodium-glucose cotransporter-2 inhibitors for improving skeletal muscle metabolism and function[J]. Basic & Clinical Medicine, 2026, 46(2): 278-281.

参考文献

[1]Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial[J]. Nat Med, 2021, 27: 1954-1960.
[2]Jhung PS, Solomon SD, Docherty KF, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF[J]. Circulation, 2021, 143: 298-309.
[3]Hashimoto Y, Takahashi F, Okamura T, et al. Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes[J]. Metabolism, 2023, 144: 155585. doi: 10.1016/j.metabol.2023.155585.
[4]Dicola S, D′amico G, Caraceni P, et al. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis[J]. J Hepatol, 2024, 81: 641-650.
[5]Zeng F, Jiang W, Chang X, et al. Sarcopenia is associated with short- and long-term mortality in patients with acute-on-chronic liver failure[J]. J Cachexia Sarcopenia Muscle, 2024, 15: 1473-1482.
[6]Latvarasku A, Rebelos E, Tuisku J, et al. SGLT2 inhibitor dapagliflozin increases skeletal muscle and brain fatty acid uptake in individuals with type 2 diabetes: a randomized double-Blind placebo-controlled positron emission tomography study[J]. Diabetes Care, 2024, 47: 1630-1637.
[7]Gao Q, Jiang Y, Song Z, et al. Dapagliflozin improves skeletal muscle insulin sensitivity through SIRT1 activation induced by nutrient deprivation state[J]. Sci Rep, 2024, 14: 16878. doi: 10.1038/s41598-024-67755-7.
[8]Conte E, Imbrici P, Dinoi G, et al. SGLT2 inhibitor dapagliflozin mitigates skeletal muscle pathology by modulating key proteins involved in glucose and ion homeostasis in an animal model of heart failure[J]. Eur J Pharmacol, 2025, 997: 177617. doi: 10.1016/j.ejphar.2025.177617.
[9]Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice[J]. EBioMedicine, 2017, 20: 137-149.
[10]Wood N, Straw S, Cheng CW, et al. Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction[J]. Eur J Heart Fail, 2024, 26: 925-935.
[11]Zhang L, Lin H, Yang X, et al. Effects of dapagliflozin monotherapy and combined aerobic exercise on skeletal muscle mitochondrial quality control and insulin resistance in type 2 diabetes mellitus rats[J]. Biomed Pharmacother, 2023, 169: 115852. doi: 10.1016/j.biopha.2023.115852.
[12]Radlinger B, Ress C, Folie S, et al. Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis[J]. Diabetologia, 2023, 66: 754-767.
[13]Winzer EB, Schauer A, Langner E, et al. Empagliflozin preserves skeletal muscle function in a HFpEF rat model[J]. Int J Mol Sci, 2022, 23: 10989. doi: 10.3390/ijms231910989.
[14]Kawakami R, Matsui H, Matsui M, et al. Empagliflozin induces the transcriptional program for nutrient homeostasis in skeletal muscle in normal mice[J]. Sci Rep, 2023, 13: 18025. doi: 10.1038/s41598-023-45390-y.
[15]Huang Q, Chen J, Liao S, et al. The SGLT2 inhibitor empagliflozin inhibits skeletal muscle fibrosis in naturally aging male mice through the AMPKα/MMP9/TGF-β1/Smad pathway[J]. Biogerontology, 2024, 25: 567-581.
[16]Tanaka K, Takahashi H, Katagiri S, et al. Combined effect of canagliflozin and exercise training on high-fat diet-fed mice[J]. Am J Physiol Endocrinol Metab, 2020, 318: e492-e503.
[17]Nakamura S, Miyachi Y, Shinjo A, et al. Improved endurance capacity of diabetic mice during SGLT2 inhibition: Role of AICARP, an AMPK activator in the soleus[J]. J Cachexia Sarcopenia Muscle, 2023, 14: 2866-2881.
[18]Lv XH, Cong XX, Nan JL, et al. Anti-diabetic drug canagliflozin hinders skeletal muscle regeneration in mice[J]. Acta Pharmacol Sin, 2022, 43: 2651-2665.
[19]Macdonald TL, Pattamaprapanont P, Cooney EM, et al. Canagliflozin prevents hyperglycemia-associated muscle extracellular matrix accumulation and improves the adaptive response to aerobic exercise[J]. Diabetes, 2022, 71: 881-893.
[20]Bamba R, Okamura T, Hashimoto Y, et al. Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice[J]. J Cachexia Sarcopenia Muscle, 2022, 13: 574-588.
[21]Xie K, Sugimoto K, Tanaka M, et al. Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats[J]. J Clin Biochem Nutr, 2023, 72: 248-255.
[22]Yang X, Wang L, Zhang L, et al. Exercise mitigates Dapagliflozin-induced skeletal muscle atrophy in STZ-induced diabetic rats[J]. Diabetol Metab Syndr, 2023, 15: 154. doi: 10.1186/s13098-023-01130-w.
[23]彭晴怡,许岭翎.1型糖尿病诱发肌少症的研究进展[J].基础医学与临床,2024,44:1189-1193.

钠-葡萄糖共转运蛋白2抑制剂改善骨骼肌代谢与功能的研究进展

Advances in sodium-glucose cotransporter-2 inhibitors for improving skeletal muscle metabolism and function

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	徐笛艳, 张雯莉, 左一丹, 苏震. 心肌和骨骼肌特异性Cyr61基因敲除小鼠模型的构建[J]. 基础医学与临床, 2025, 45(6): 720-726.
[2]	谢东格, 李俊豪, 韩晗, 李寿田. 经典瞬时受体电位通道在骨骼肌疾病中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1309-1312.
[3]	黄李晨露, 张家瑞, 郑永钦, 贺军栋. 钠-葡萄糖共转运蛋白2抑制剂在非酒精性脂肪性肝病中作用的研究进展[J]. 基础医学与临床, 2023, 43(10): 1594-1598.
[4]	刘晓军孔星星朱镠娈崔安芳纪少伟常永生方福德. Par6A cDNA的克隆与表达[J]. 基础医学与临床, 2009, 29(5): 459-463.
[5]	谢瑞芹李荣芹崔炜. 骨骼肌缺血预适应对猪心肌MMP-2、MMP-9和TIMP-1的影响[J]. 基础医学与临床, 2006, 26(3): 280-280.